Skip to main content

Select Drug Profiles

FDA Approvals, Leukemia, Oncology

Oral Onureg First Drug Approved for Adults with AML in Remission

Danyelza Receives FDA Approval for High-Risk Neuroblastoma in the Bone and Bone Marrow

Gavreto, a New RET Inhibitor, Now Approved for Thyroid Cancer with RET Fusions

The Dirty Dozen Redux

David B. Nash, MD, MBA

David B. Nash, MD, MBA

ESMO 2020 Highlights

Olaparib a New Option for Men with Metastatic Prostate Cancer and BRCA Mutation

Phoebe Starr

ESMO 2020 Highlights

Nivolumab New Standard of Care in Gastroesophageal Cancers as First-Line or Adjuvant Therapy

Phoebe Starr

Pandemic Posting

David B. Nash, MD, MBA

David B. Nash, MD, MBA

Politics and Healthcare: Drug Pricing Dynamics Leading Up to the 2020 Election

Gary Branning, MBA, Kathryn Hayes, BA

Gary Branning, MBA; Kathryn Hayes, BA

Original Research, Practice Management

Economic Implications of Preventing Major Cardiovascular and Limb Events with Rivaroxaban plus Aspirin in Patients with Coronary or Peripheral Artery Disease in the United States

Luis Hernandez, MSc, MPH, Anshul Shah, BS Pharm, MS, Qi Zhao, MD, Dejan Milentijevic, PhD, MBA, Akshay Kharat, PhD

Luis Hernandez, MSc, MPH; Anshul Shah, BS Pharm, MS; Qi Zhao, MD; Dejan Milentijevic, PhD, MBA; Akshay Kharat, PhD

Original Research, Practice Management

Economic Burden of Neurologic Toxicities Associated with Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States

Michael S. Broder, MD, MSHS, Qiufei Ma, PhD, Tingjian Yan, PhD, Jie Zhang, PhD, Eunice Chang, PhD, David Kuzan, MD, Lamis Eldjerou, MD

Michael S. Broder, MD, MSHS; Qiufei Ma, PhD; Tingjian Yan, PhD; Jie Zhang, PhD; Eunice Chang, PhD; David Kuzan, MD; Lamis Eldjerou, MD

Page 28 of 244
Results 271 - 280 of 2434